Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan

Journal of the Formosan Medical Association

Volumn 106, Issue 4, 2007, Pages 281-287

  Chang, Hsiu Hao ^a   Yang, Yung Li ^a   Hung, Mei Hua ^a   Tasy, Woei ^a   Shen, Ming Ching ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Hemophilia B; Pharmacokinetic study; Recombinant FIX; Taiwan

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERABILITY; HEMOPHILIA B; HUMAN; IN VIVO STUDY; LABORATORY TEST; MAXIMUM PLASMA CONCENTRATION; PHYSICAL EXAMINATION; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TAIWAN; THROMBOSIS; VITAL SIGN;

EID: 34248659669     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60253-9     Document Type: Article

References (37)

1. Hule V, Nespurkova M. Congenital factor IX deficiency (Christmas), hemophilia B. Ann Paediatr 1956;186:175-81.
2. Choo KH, Gould KG, Rees DJ, et al. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature 1982; 299:178-80.
3. Anson DS, Choo, KH, Rees DJ, et al. The gene structure of human anti-haemophilic factor IX. Embo J 1984;3: 1053-60.
4. Zhang K, Kurachi S, Kurachi K. New function for age-related stability element in conferring strict tissue-specific expression of human factor IX and protein C genes. Thromb Haemost 2002;88:537-8.
5. Manco-Johnson MJ, Riske B, Kasper CK. Advances in care of children with hemophilia. Semin Thromb Hemost 2003; 29:585-94.
6. Brinkhous KM, Sigman JL, Read MS, et al. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 1996;88: 2603-10.
7. Djulbegovic B, Marasa M, Pesto A, et al. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B. Am J Hematol 1996;51:168-70.
8. Warrier I, Kasper CK, White GC II, et al. Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group. Am J Hematol 1995; 49:92-4.
9. Kim HC, McMillan CW, White GC, et al. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992;79:568-75.
10. Foster PR. Prions and blood products. Ann Med 2000;32: 501-13.
11. Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001;98:3600-6.
12. Adamson S, Charlebois T, O'Connell B, et al. Viral safety of recombinant factor IX. Semin Hematol 1998;35:22-7.
13. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55:638-48.
14. Ragni MV, Pasi KJ, White GC, et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002;8:91-7.
15. White G, Shapiro A, Ragni M, et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998;35:33-8.
16. Ewenstein BM, Joist JH, Shapiro AD, et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002;42:190-7.
17. Poon MC, Lillicrap D, Hensman C, et al. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 2002;87:431-5.
18. Kirkwood TB, Snape TJ. Biometric principles in clotting and clot lysis assays. Clin Lab Haematol 1980;2:155-67.
19. Cinotti S, Longo G, Messori A, et al. Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study. Thromb Res 1991;61: 385-93.
20. Shen MC. One hundred and two cases of hemophilia A in Taiwan. I. Clinical, laboratory and family studies. Taiwan Yi Xue Hui Za Zhi 1982;81:190-206.
21. Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224-32.
22. Hoag MS, Johnson FF, Robinson JA, et al. Treatment of hemophilia B with a new clotting-factor concentrate. N Engl J Med 1969;280:581-6.
23. Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003;9(Suppl 1):94-100.
24. Thompson DF. Citation analysis of selected clinical pharmacology journals. Hosp Pharm 1991;26:437-9.
25. White GC II, Shapiro AD, Kurczynski EM, et al. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. Thromb Haemost 1995;73:779-84.
26. Berntorp E, Bjorkman S, Carlsson M, et al. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost 1993;70:768-73.
27. Liebman HA, Rosenwald-Zuckerman T, Retzios A, et al. Kinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacement. Haemophilia 1999;5:174-90.
28. Goldsmith JC, Kasper CK, Blatt PM, et al. Coagulation factor IX: successful surgical experience with a purified factor IX concentrate. Am J Hematol 1992;40:210-5.
29. Bjorkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994;46:325-32.
30. Poon MC, Aledort LM, Anderle K, et al. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 1995;35:319-23.
31. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001;40:815-32.
32. Bjorkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7:133-9.
33. Heimark RL, Schwartz SM. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun 1983;111:723-31.
34. Kohler M, Seifried E, Hellstern P, et al. In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standards. Blut 1988;57:341-5.
35. Goudemand J, Peynet J, Chambost H, et al. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. Thromb Haemost 1998;80:919-24.
36. Bond M, Jankowski M, Patel H, et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35:11-7.
37. White GC II, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997;78:261-5.